ADAG
Adagene Inc.
stockNASDAQADR
adagene was co-founded by two serial entrepreneurs to power antibody discovery. its aim is to become the leading player in antibody discovery and engineering. it has developed a proprietary dynamic precision library (dpl) and is showcasing the power of the library with a unique pipeline of innovative antibody therapeutics that is advancing into clinical trials. adagene previously has raised three series of financing with over $86 million. investors include f-prime capital (formerly fidelity biosciences), eight roads ventures china (formerly fidelity growth partners asia), 6 dimensions capital, gp healthcare capital, sequoia china, and new world tmt. for more information, please visit www.adagene.com.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 2.00 | 2026-11-06 | -12.00% | 4.136 |
| 1M | 2.46 | 2026-10-13 | -28.45% | 3.798 |
| 3M | 3.72 | 2026-08-13 | -52.69% | 2.918 |
| 6M | 3.70 | 2026-05-13 | -52.43% | 1.973 |
| 1Y | 1.80 | 2025-11-13 | -2.22% | 1.530 |
| 2Y | 2.37 | 2024-11-13 | -25.74% | — |
| 5Y | 11.00 | 2021-11-12 | -84.00% | 0.186 |
Adagene Inc. (NASDAQ:ADAG) stock price today is $1.76, and today's volume is 126,467. ADAG is down 12.000% today. The 30 day average volume is 284,644. ADAG market cap is $118.17M with 67.14M shares outstanding.